Abbott Laboratories has received Chinese State Food and Drug Administration (SFDA) clearance for its Xience V everolimus-eluting coronary stent system.
The Abbott Park, IL-based firm plans a fourth-quarter launch in China for Xience V, which is designed for the treatment of coronary artery disease.
Related Reading
Abbott takes Xience Prime stent overseas, August 31, 2009
Medtronic, Abbott bury patent-dispute hatchet, July 27, 2009
Abbott begins U.S. trial of Absolute Pro stent, April 1, 2009
Abbott gets FDA nod for Xience V, July 3, 2008
U.S. panel backs Abbott's drug-coated heart stent, December 3, 2007
Copyright © 2009 AuntMinnie.com
